Providing Cancer Care Closer to Home for Patients With Multiple Myeloma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-08

Study Completion Date

2024-03-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There is very limited data on the utilization of National Cancer Institute Comprehensive Cancer Center (NCI-CCC) satellite sites in general. Of what is available, most is in regards to providing chemotherapy at facilities closer to patients' home. These "satellite chemotherapy infusion centers", typically community-based treatment locations at community hospitals/facilities, freestanding clinics, or mobile units, are reported to be well liked by patients who utilize their services and reduce their travel times and expenses. In these studies patients still remained in the care of their current provider and site and are required to travel to the site for clinical visits and other appointments. It is currently unknown if patients are willing to transfer their care to a different provider to alleviate travel burden. In addition, although increased travel burden has been lower quality of life in cross-sectional studies, no data exists suggesting that these reducing travel burden can improve these outcomes intra-patient, to the knowledge of the investigators.

The patient roles of the multiple myeloma clinical providers at the Siteman primary location have grown in recent years. The providers have determined a need to refer some patients to the satellite sites to relieve congestion at the site while also hopefully improving the clinical experience for those patients. This study is a natural experiment of this process.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms

NCT02756572

Blasts 10 Percent or More of Bone Marrow Nucleated Cells Chronic Myelomonocytic Leukemia-2 High Grade Malignant Neoplasm +6 more

COMPLETED PHASE2

Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

NCT00024466

Multiple Myeloma

COMPLETED PHASE1/PHASE2

Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain

NCT03523351

Metastatic Solid Tumors of Metastatic Disease

COMPLETED PHASE1/PHASE2

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Multiple Myeloma

NCT00002552

Lymphoma Multiple Myeloma and Plasma Cell Neoplasm

COMPLETED PHASE2

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00004903

Multiple Myeloma and Plasma Cell Neoplasm

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Care transition

-At baseline, the participant and the provider will make a decision on if the participant will transfer care to a satellite location.

Group Type EXPERIMENTAL

Care transition

Intervention Type OTHER

Cancer care is transitioned to a satellite site.

No care transition

-At baseline, the participant and the provider will make a decision on if the participant will transfer care to a satellite location.

Group Type ACTIVE_COMPARATOR

No care transition

Intervention Type OTHER

Cancer care is not transitioned to a satellite site.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Care transition

Cancer care is transitioned to a satellite site.

Intervention Type OTHER

No care transition

Cancer care is not transitioned to a satellite site.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Eligibility Criteria

* At least 18 years old
* Diagnosed with multiple myeloma
* Receiving care from a provider within the Division of Oncology at the primary Siteman Cancer Center site
* Resides within the catchment area of a Siteman Cancer Center satellite site
* Able to read, speak, and understand English
* Willing to provide informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No